Search       
 

About 24X7
Contact Us
Subscribe
Read Weekly eNewsletter
HOME | NEWS | CURRENT ISSUE | BUYER'S GUIDE | CLASSIFIEDS | ARCHIVES | CALENDAR | RESOURCES | CAREERS

Top News

Page 1 of 140


PCI safe during continuing anticoagulant therapy    May 12, 2008
NEW YORK (Reuters Health) - Percutaneous coronary intervention (PCI) can be conducted safely during uninterrupted oral anticoagulant treatment, according to Finnish researchers.
US court hears claim linking vaccines to autism    May 12, 2008
Ranbaxy to develop anti-infective drugs for Merck    May 12, 2008
LONDON/MUMBAI (Reuters) - India's Ranbaxy Laboratories Ltd is to develop new anti-infective drugs for Merck & Co Inc, underlining the growing use of Indian pharmaceutical research by multinational companies.
Forest ends promotion of Daiichi hypertension drug    May 12, 2008
NEW YORK (Reuters) - Forest Laboratories Inc has ended its agreement with Daiichi Sankyo Co Ltd to co-promote Daiichi's blood-pressure drug Azor, as Forest shifts resources to support other products, the companies said on Monday.
RESEARCH ALERT: M. Stanley cuts ImClone to underweight    May 12, 2008
BANGALORE (Reuters) - Morgan Stanley downgraded ImClone Systems Inc to "underweight" from "equal-weight," saying the biotechnology company's cancer drug Erbitux is likely to be a disappointment.
DITEC to Hold its 2K8 Conference    May 12, 2008
DITEC will once again present its DITEC 2K8 Continuing Education Conference & National Vendor Exhibit from May 21 through May 23 in Cleveland.
Zimmer chief marketing officer to leave company    May 9, 2008
CHICAGO (Reuters) - Orthopedic device maker Zimmer Holdings Inc said on Friday its chief marketing officer, Sheryl Conley, would leave the company effective May 16.
ANALYSIS-Economy dims dental industry's smile    May 9, 2008
NEW YORK (Reuters) - Makers of dental veneers aren't smiling so brightly these days as the slowing U.S. economy weakens demand for expensive optional treatments.
EARNINGS POLL-Cost cuts seen narrowing Crucell's Q1 loss    May 9, 2008
AMSTERDAM (Reuters) - Dutch biotechnology firm Crucell is expected to report a smaller first-quarter net loss, thanks to cost cuts and improved operating margins.
EARNINGS POLL-Solvay Q1 profit down on dollar, input costs    May 9, 2008
BRUSSELS (Reuters) - Belgian drugs, chemicals and plastics maker Solvay will report a 9 percent fall in first-quarter operating profit on Tuesday due to the weak dollar, commodity price spikes and a depressed building sector.
Sanofi hit by generic Plavix threat in Europe    May 9, 2008
LONDON (Reuters) - French drugmaker Sanofi-Aventis, which briefly encountered generic competition to its second-biggest product Plavix in the United States in 2006 and 2007, now faces a similar threat in Europe.
Mylan posts bigger loss after charges; shares fall    May 9, 2008
NEW YORK (Reuters) - Drugmaker Mylan Inc on Thursday reported a wider first-quarter loss due to lower U.S. sales of generic medicines and special charges, although overall revenue more than doubled after a recent acquisition.
Longs Drug April same-store sales hurt by Easter shift    May 9, 2008
BANGALORE (Reuters) - Longs Drug Stores Corp posted a 1.5 percent drop in April sales at stores open at least a year, hurt by the shift of Easter to March.
Roche arthritis drug Actemra backed by fifth study    May 9, 2008
ZURICH (Reuters) - Swiss drugmaker Roche said on Friday its Actemra drug for rheumatoid arthritis had proved effective in a fifth late-stage study that boosts its chance of bumper sales.
Hungary's Richter lowers sales outlook after Q1    May 9, 2008
BUDAPEST (Reuters) - Hungarian drug maker Richter Gedeon delivered first-quarter operating figures in line with market expectations on Friday but lowered its sales outlook for some key markets, including the U.S. and Hungary.
Schweizerhall plans German generic Plavix launch    May 9, 2008
LONDON (Reuters) - Schweizerhall, a generic drug company based in Basel, said on Friday it was close to winning approval for a generic version of Sanofi-Aventis's blockbuster blood thinning drug Plavix in Germany.
Takeda sees big profit slump on Millennium costs    May 9, 2008
TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co Ltd posted a 7.7 percent fall in annual operating profit on Friday and forecast a sharp drop for the current year on costs for its $8.8 billion purchase of U.S. biotech firm Millennium Pharmaceuticals.
Osiris to sell unit to NuVasive for up to $85 mln    May 9, 2008
BANGALORE (Reuters) - Osiris Therapeutics Inc said it agreed to sell its Osteocel business to medical device maker NuVasive Inc for $85 million, including potential milestone payments, sending its shares up 15 percent. NuVasive will buy the business for $35 million in cash, and additional milestone-based payments of up to $50 million in either cash or a combination of cash and stock.
Alabama Biomeds Launch New Group    May 9, 2008
Biomeds have organized to form the new Alabama Biomedical Society, which will hold its kickoff meeting on Saturday, May 17 in Birmingham, Ala.
Barr Pharma profit disappoints, shares down 23 pct    May 8, 2008
NEW YORK (Reuters) - Barr Pharmaceuticals Inc reported disappointing first-quarter profit on weak U.S. sales and slashed its full-year forecast on Thursday, driving its shares down 23 percent to their lowest levels since late 2004.
Stryker to raise spending on quality, compliance    May 8, 2008
CHICAGO (Reuters) - Stryker Corp said on Thursday it plans to spend $50 million in 2008 to improve its quality and compliance as it works to resolve issues with federal health regulators.
Incidental findings on cardiac multidetector row CT common for healthy adults    May 8, 2008
NEW YORK (Reuters Health) - Incidental findings are common among healthy older adults who undergo cardiac multidetector row computed tomography (MDCT), according to a report in the April 14th issue of the Archives of Internal Medicine.
Labopharm's loss grows as revenue drops    May 8, 2008
TORONTO (Reuters) - Labopharm Inc said on Thursday that its first-quarter loss deepened as revenue fell and research costs grew.
Biovail to shift focus, shut plants as profit dips    May 8, 2008
TORONTO (Reuters) - Biovail Corp said on Thursday that it will close operations in Puerto Rico, resulting in charges of $80 million to $100 million in the next few quarters, as it shifts focus to a new line of drugs.
Innogenetics: up to 40 redundancies in labour plan    May 8, 2008
BRUSSELS (Reuters) - Belgian biotech company Innogenetics said on Thursday it expected a maximum 40 staff to be made redundant following a collective labour agreement.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69

70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86

87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102

103
104
105
106
107
108
109
110
111
112
113
114
115
116

117
118
119
120
121
122
123
124
125
126
127
128
129
130

131
132
133
134
135
136
137
138
139
140
Resources
Media Kit
Editorial Advisory Board
Advertiser Index
Reprints
News | Current Issue | Buyer's Guide | Classifieds | Archives | Calendar | Resources | Careers
About 24X7 | Contact Us | Subscribe | Read Weekly eNewsletter
Media Kit | Editorial Advisory Board | Advertiser Index | Reprints
Allied Healthcare
24X7 |  Chiropractic Products Magazine |  Clinical Lab Products (CLP) |  Orthodontic Products |  The Hearing Review
Hearing Products Report (HPR) |  HME Today |  Rehab Management |  Physical Therapy Products |  Plastic Surgery Products
Imaging Economics |  Medical Imaging |  RT |  Sleep Review
Medical Education
SynerMed Communications |  IMED Communications
Practice Growth
Practice Builders
Copyright © 2008 Ascend Media LLC | 24X7 | All Rights Reserved. Privacy Policy | Terms of Service